Navigation Links
Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets
Date:10/26/2011

SAN FRANCISCO, Oct. 26, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2011 on Wednesday, November 2, 2011, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Thursday, December 1, 2011. To access the conference call, follow these instructions:Dial: (866) 203-3436 (U.S.); (617) 213-8849 (international)Passcode: 16610535 (Nektar Therapeutics is the host)An audio replay will also be available shortly following the call through Thursday, December 1, 2011 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 41636531.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for NKTR-118, an investigationa
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
2. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
3. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
4. Nektar to Announce Financial Results for the Second Quarter of 2011 on Thursday, August 4, 2011, After Close of U.S.-Based Financial Markets
5. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
6. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
7. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
8. Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
10. Nektar Therapeutics President and CEO Howard W. Robin to Present at the 31st Annual Cowen and Company Healthcare Conference in Boston
11. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2010 on Tuesday, March 1, 2011, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015   AMC Health , the leading ... improving the effectiveness and efficiency of healthcare for ... and Jared Wilstead have joined ... Strategic Client Development, and Wilstead will serve as ... Health,s commitment to accelerating the adoption of monitored ...
(Date:3/5/2015)... 5, 2015  AMRI (NASDAQ: AMRI ) ... newly created position of VP of International Sales, effective ... Vice President of Global Sales and Marketing. ... international sales team in an effort to increase worldwide ... segments. Mr. Pettersson will drive strategy for sales and ...
(Date:3/5/2015)... , March 5, 2015  ANI Pharmaceuticals, Inc. ... that it has acquired the approved abbreviated new ... 50mg, 100mg and 150mg, previously marketed by Teva ... for this product was approximately $39 million in ... , President and CEO of ANI Pharmaceuticals, stated, ...
Breaking Medicine Technology:AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 2AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 3AMRI Hires VP of International Sales 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3
... Current family planning,use prevents over one million ... to further reduce the number of infants born ... Reports, "Family Planning,Choices for Women With HIV," published ... of Public Health, Center for Communication Programs. ...
... Coalition unites women in joining the fight for, education and ... ... cancer, WASHINGTON, Sept. 21 More than 80 women and,men ... Washington,D.C. to attend the First Annual Cervical Cancer/HPV Conference, conducted,by the ...
Cached Medicine Technology:Hopkins Report: Focusing on Family Planning Lessens HIV Impact 2Hopkins Report: Focusing on Family Planning Lessens HIV Impact 3The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy 2The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy 3The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy 4
(Date:3/5/2015)... The global digital PCR (dPCR) and qPCR market is expected to ... to 2019. , The global digital PCR (dPCR) and qPCR market ... to 2019. Although the mature markets such as the U.S., Germany, ... and qPCR market the Asia-Pacific region is expected to grow at ... of the digital PCR (dPCR) and qPCR market is driven by ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 This ... formaldehyde in low-cost laminate flooring products, initiating ... manufacturer of eco-friendly building materials made primarily from ... by testing all their flooring products for volatile ... laboratory Benchmark International (BMH). Results from ...
(Date:3/5/2015)... AxoGen, Inc. (NASDAQ: AXGN) , a leading ... market, reported record revenue of $4.79 million for the ... million in the year-ago fourth quarter demonstrating the Company’s ... strong fourth quarter revenue growth reflects the market’s growing ... driving increased surgeon adoption of our unique product portfolio ...
(Date:3/5/2015)... New York, New York (PRWEB) March 05, 2015 ... behalf of men who allegedly suffered heart attacks, strokes ... of prescription low testosterone therapies continue to move forward ... District Court, Northern District of Illinois. According to a ... has set forth procedures for the use of master ...
(Date:3/5/2015)... RI (PRWEB) March 05, 2015 Rhode Island ... third year in a row to support the Providence College ... The donation covered the purchase of the ‘Think Pink’ uniforms, ... against Big East Conference opponent DePaul University at Alumni Hall/Mullaney ... to continue our support of the PC women’s basketball’s ‘Pink ...
Breaking Medicine News(10 mins):Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2
... test of the first vaccine against hepatitis E, a form ... spread// to soldiers or other Western visitors to the region. ... an engineered virus, was 96 percent effective for Nepalese Army ... widespread even in a group without the vaccine: only 7 ...
... in an online medical training system has caused chaos ... British Medical Association has criticized//his electronic procedure of hiring ... jobless. ,The Medical Training Application Service was ... post of specialist trainee. The deadline for the receipt ...
... if consumed in moderate quantities is expected to aid in ... called as the Zutphen Study.// ,According to this ... cardiovascular deaths and increase the life span in middle aged ... the first time that a specific genre of alcohol is ...
... cancer have a slightly better long-term side effects profile ... to a study.// ,Doctors in France conducted ... stage prostate cancer to evaluate a man’s quality of ... based on the type of treatment the patient received: ...
... out with findings that encourage better care of our mouths, ... ,American and British researchers have combined study results ... blood flow through the arteries and heart, and thereby prevent ... developed nations. ,The work of these scientists has ...
... for Japanese patients looking for organ transplantation.// ... foreign patients in Chinese hospitals, more people, frustrated with ... receiving transplants in their homeland are turning to the ... ,Kenichi Hokamura, 63, of the southern Japanese ...
Cached Medicine News:Health News:Prostate Brachytherapy Causes Fewer Side Effects Than Surgery 2Health News:Good Oral Health Equals Good Health for Your Heart 2
... Estriol (E3) is one of the 3 ... estradiol and estrone). In terms of estrogenic ... estradiol [1]. Estriol is produced almost exclusively ... produced in the normal human fetus. During ...
... Estrone Sulfate (E1S) is the most abundant ... as normal men [1,2]. Estrone Sulfate is ... and has a longer half-life in blood ... generally parallel those of estrone and estradiol, ...
Helmer's Horizon Series line of refrigerators are designed specifically for the cost conscious buyer. This line offers outstanding performance, quality, and the features you need to ensure the safety...
... the i.Series refrigerator iB120, ... for the blood bank. ... than ever before, i.Series ... at the forefront of ...
Medicine Products: